Literature DB >> 9748568

DNA sequence selectivity of topoisomerases and topoisomerase poisons.

G Capranico1, M Binaschi.   

Abstract

Chemical agents able to interfere with DNA topoisomerases are widespread in nature, and some of them have clinical efficacy as antitumor or antibacterial drugs. Drugs which have as a target DNA topoisomerases could be divided into two categories: poisons and catalytic inhibitors. Classical topoisomerase poisons stimulate cleavage in a sequence-selective manner, yielding drug-specific cleavage intensity pattern. The mechanisms of drug interaction with DNA topoisomerases, the DNA sequence selectivity of the action of topoisomerase II poisons and the identification of structural determinants of their activity have suggested that topoisomerase II poisons may fit into a specific pharmacophore, constituted by a planar ring system with DNA intercalation or intercalation-like properties, and protruding side chains interfering with the protein side of the covalent enzyme-DNA complex. The complete definition of the diverse pharmacophores of topoisomerase II poisons will certainly be of value for the design of new agents directed to specific genomic sites, and more effective in the treatment of human cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9748568     DOI: 10.1016/s0167-4781(98)00135-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  35 in total

Review 1.  The yeast two-hybrid system and its pharmaceutical significance.

Authors:  Z Topcu; K L Borden
Journal:  Pharm Res       Date:  2000-09       Impact factor: 4.200

2.  Structure and hydration of the DNA-human topoisomerase I covalent complex.

Authors:  G Chillemi; T Castrignanò; A Desideri
Journal:  Biophys J       Date:  2001-07       Impact factor: 4.033

3.  Position-specific trapping of topoisomerase I-DNA cleavage complexes by intercalated benzo[a]- pyrene diol epoxide adducts at the 6-amino group of adenine.

Authors:  Y Pommier; G S Laco; G Kohlhagen; J M Sayer; H Kroth; D M Jerina
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

Review 4.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

5.  Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.

Authors:  Katie J Aldred; Sylvia A McPherson; Pengfei Wang; Robert J Kerns; David E Graves; Charles L Turnbough; Neil Osheroff
Journal:  Biochemistry       Date:  2011-12-16       Impact factor: 3.162

6.  Atypical cytostatic mechanism of N-1-sulfonylcytosine derivatives determined by in vitro screening and computational analysis.

Authors:  Fran Supek; Marijeta Kralj; Marko Marjanović; Lidija Suman; Tomislav Smuc; Irena Krizmanić; Biserka Zinić
Journal:  Invest New Drugs       Date:  2007-09-27       Impact factor: 3.850

Review 7.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

Review 8.  Drugging topoisomerases: lessons and challenges.

Authors:  Yves Pommier
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

9.  Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.

Authors:  Ryan P Bender; Michael J Jablonksy; Mohammad Shadid; Ian Romaine; Norma Dunlap; Clemens Anklin; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2008-03-21       Impact factor: 3.162

10.  Mechanistic studies of the modulation of cleavage activity of topoisomerase I by DNA adducts of mono- and bi-functional PtII complexes.

Authors:  Jaroslav Malina; Oldrich Vrana; Viktor Brabec
Journal:  Nucleic Acids Res       Date:  2009-07-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.